Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

AIMS: The efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear. Therefore, this study aims to assess the effect of PCSK9 inhibitors (alirocumab and evolocumab) on ASCVD patients co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hong-Fei, Mao, Yu-Cheng, Xu, Xin-Yi, Zhao, Si-Yu, Han, Dan-Dan, Ge, Shi-Yao, Song, Kai, Geng, Chang, Tian, Qing-Bao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755489/
https://www.ncbi.nlm.nih.gov/pubmed/36531722
http://dx.doi.org/10.3389/fcvm.2022.1016802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755489/
https://www.ncbi.nlm.nih.gov/pubmed/36531722
http://dx.doi.org/10.3389/fcvm.2022.1016802

Ejemplares similares